<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81724">
  <stage>Registered</stage>
  <submitdate>13/12/2006</submitdate>
  <approvaldate>29/01/2007</approvaldate>
  <actrnumber>ACTRN12607000093482</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of Albumin Interferon Alfa-2b with Ribavirin Compared to Peg-Interferon Alfa-2a with Ribavirin in interferon Naive Patients, Genotype-1</studytitle>
    <scientifictitle>Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C (CHC) Genotype 1 to improve Sustained virologic response. ACHIEVE-1</scientifictitle>
    <utrn />
    <trialacronym>ACHIEVE-1</trialacronym>
    <secondaryid>Human Genome Sciences: HGS1008-C1060</secondaryid>
    <secondaryid>ClinicalTrials.gov: NCT00402428</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatits C</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subcutaneous injections of albumin interferon alfa-2b 900mcg or 1200mcg every 2 weeks and oral administration of ribavirin 1000 or 1200mg daily.  Duration: 48 week treatment.</interventions>
    <comparator>Subcutaneously injection of peginterferon alfa-2a 180mcg weekly and oral administration of ribavirin 1000 or 1200mg daily.  Duration: 48 week treatment.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virologic response (SVR).</outcome>
      <timepoint>Week 72.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rapid virologic response</outcome>
      <timepoint>at Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Early virologic response</outcome>
      <timepoint>at Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Undetectable hepatitis C virus ribonucleic acid (HCV RNA)</outcome>
      <timepoint>at Week 24 and Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Normalization of ALT (a liver enzyme) over the duration of the study</outcome>
      <timepoint>Day 0, Weeks 2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 52, 60, 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life evaluation throughout the duration of the study</outcome>
      <timepoint>Day 0, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments throughout the duration of the study</outcome>
      <timepoint>Day 0, Weeks 2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 52, 60, 72</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key Inclusion Criteria: Diagnosis of chronic hepatitis C.Liver biopsy performed within 2 years of Day 0 or during screening.Infected with hepatitis C virus genotype 1.Interferon alfa treatment na√Øve (ie, have never been treated with an interferon product).Subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin.Have compensated liver disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Key Exclusion Criteria:Decompensated liver disease including those subjects with a past history or presence of ascites, bleeding varices or hepatic encephalopathy.History of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt.Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen (HBsAG).Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, Wilsons Disease, or alpha 1-antitrypsin deficiency.A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).Active seizure disorder within the last 2 years.Organ transplant other than cornea and hair transplant.Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).Cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix).Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone treatment program may be enrolled in the study.Received any experimental agent within 28 days prior to Day 0.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by Interactive Voice Response System (IVRS)</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software. Stratified allocation. Stratification factors are HCV RNA (&gt;800,000 or &lt;800,000) at screening, Body Mass Index (BMI) at Day 0, Race (Black/African American or all others).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>30/12/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1290</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Human Genome Sciences, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Human Genome Sciences Europe GmbH</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Human Genome Sciences Pacific Pty Ltd.</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who are IFNa treatment naive.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metropolitan Research</ethicname>
      <ethicaddress>Fairfax, Virginia, United States 22031</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Florida - Gainesville</ethicname>
      <ethicaddress>Gainesville, Florida, United States  32610</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Platek</name>
      <address>14200 Shady Grove Road
Rockville MD 20850</address>
      <phone>1-866-447-9749</phone>
      <fax />
      <email>Thomas_Platek@hgsi.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Thomas Platek</name>
      <address>14200 Shady Grove Road
Rockville MD 20850</address>
      <phone>1-866-447-9749</phone>
      <fax />
      <email>Thomas_Platek@hgsi.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>